Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer

Ann Oncol. 2012 Aug;23(8):2204-2205. doi: 10.1093/annonc/mds221. Epub 2012 Jul 5.

Authors

G Gullo¹, M Zuradelli², F Sclafani³, A Santoro², J Crown³

Affiliations

¹ Department of Oncology, St Vincent's University Hospital, Dublin, Ireland. Electronic address: g.gullo@svuh.ie.
² Oncology and Haematology Unit, Humanitas Cancer Center, Rozzano, Italy.
³ Department of Oncology, St Vincent's University Hospital, Dublin, Ireland.

PMID: 22767587
DOI: 10.1093/annonc/mds221

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Antibodies, Monoclonal, Humanized / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / enzymology*
Breast Neoplasms / pathology
Carboplatin / administration & dosage
Docetaxel
Female
Humans
Middle Aged
Receptor, ErbB-2 / biosynthesis
Receptor, ErbB-2 / genetics
Receptor, ErbB-2 / metabolism*
Retrospective Studies
Taxoids / administration & dosage
Trastuzumab

Substances

Antibodies, Monoclonal, Humanized
Taxoids
Docetaxel
Carboplatin
Receptor, ErbB-2
Trastuzumab